The Role of Biosimilars in Value-Based Oncology Care

Cancer Management and Research - New Zealand
doi 10.2147/cmar.s164201
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

Tendering and Biosimilars: What Role for Value-Added Services?

Journal of Market Access & Health Policy
2019English

Barriers to Oncology Biosimilars Uptake in the United States

Oncologist
Cancer ResearchMedicineOncology
2018English

The “Value” of Value in Gynecologic Oncology Practice in the United States: Society of Gynecologic Oncology Evidence-Based Review and Recommendations

Gynecologic Oncology
GynecologyOncologyObstetrics
2017English

The Role of Radiation Oncology in Immuno‐Oncology

Oncologist
Cancer ResearchMedicineOncology
2019English

The Role of Biosimilars in the Treatment of Rheumatic Diseases

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2012English

The Role of Biosimilars in the Treatment of Rheumatic Diseases

Clinical pharmacology and therapy
2018English

The Role of Value Drivers in Value-Based Management Concept

Herald UNU. International Economic Relations And World Economy
2019English

Oncology Nursing Is Evidence-Based Care

Clinical Journal of Oncology Nursing
Oncology
2016English

Value-Based Care in Hepatology

Hepatology
MedicineHepatology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy